Dirithromycin is a new macrolide antibiotic with an active metabolite, erythromycylamine. We evaluated the in vitro activities of both drugs against 16 isolates of Chiamydia trachomatis and compared them with that of doxycycline. In vitro susceptibility testing was performed with McCoy cell monolayers. The MIC was defined as the lowest concentration of antibiotic without inclusions. The MBC was defined as the lowest concentration of antibiotic yielding no inclusions after passage onto 24-h-old antibiotic-free McCoy cell monolayers. Dirithromycin and erythromycylamine appeared to be equally effective against these 16 strains of C. trachomatis (MIC for 90%o of strains tested, mg/ml; MBC for 90% of strains tested, 2 p,g/ml). Both were less active than doxycycline (MIC for 90%o of strains tested, 0.06 ,g/ml; MBC for 90%o of strains tested, 0.12 ,ug/ml). The combination of dirithromycin and erythromycylamine appeared to be additive.
Dirithromycin is a new macrolide antibiotic which is metabolized to an active compound, erythromycylamine (2) . It has in vitro activity comparable to that of erythromycin (9) . Like erythromycin, dirithromycin is concentrated intracellularly (3) . Erythromycin and other macrolides have been shown to have both in vitro and in vivo activity against Chlamydia trachomatis (1, 4, 5, 7) . However, there is no published information on the activity of dirithromycin against C. trachomatis. Therefore, we tested the in vitro activities of dirithromycin and erythromycylamine against clinical isolates of C. trachomatis and compared them with that of doxycycline, an antibiotic commonly used to treat C. trachomatis infections. We also tested dirithromycin and erythromycylamine for synergy.
Dirithromycin and erythromycylamine were obtained from Lilly Pharmaceuticals (Indianapolis, Ind.), and doxycycline was obtained from Sigma Chemicals (St. Louis, Mo. The antimicrobial susceptibility of C. trachomatis was determined by using 96-well dilution plates as previously described (6) Dirithromycin and erythromycylamine demonstrated equivalent activities against the C. trachomatis stains tested ( Table  1) . Both of these drugs were significantly less active than doxycycline. The fractional inhibitory concentration index of dirithromycin plus erythromycylamine for all 16 C. trachomatis strains tested was 1. Infections caused by C. trachomatis are the most common bacterial sexually transmitted infections in the United States. It is estimated that over 4.5 million cases occur annually (8) . Unlike other sexually transmitted diseases, the incidence of Chlamydia infections remains fairly constant (8) . Therefore, it is necessary to evaluate newer drugs for the treatment of C. trachomatis infections. In this study, dirithromycin and erythromycylamine were equally active against the recent clinical isolates tested and the combination of dirithromycin and erythromycylamine was additive for all of the strains tested. However, doxycycline was more active than dirithromycin or erythromycylamine.
Dirithromycin has been shown to achieve high concentrations in tissue despite low concentrations in serum (3) . It has a long terminal half-life of 20 to 50 h, and concentrations in tissue reach a maximum between 5 to 10 h postdose (3). Therefore, dirithromycin can be administered once daily. These properties make dirithromycin very attractive for the potential treatment of C. trachomatis infections. However, since dirithromycin is less active than doxycycline, any potential advantage of dirithromycin over doxycycline in the treat- ment of C. trachomatis would be its improved pharmacokinetic properties.
